Information Provided By: 
Fly News Breaks for June 3, 2019
CRTX
Jun 3, 2019 | 08:27 EDT
Credit Suisse analyst Martin Auster started coverage of Cortexyme with an Underperform rating and $14 price target. The analyst notes that this is a "high-risk, high-reward" Alzheimer's disease speculation with multi-billion annual revenue potential should COR388 prove marketable. However, disease-modifying AD drug development has universally failed so far, owing to a limited understanding of disease pathology, he contended.
News For CRTX From the Last 2 Days
There are no results for your query CRTX
